Our strength is in our breadth
by MARTIN LANEJANUARY 18, 2021
Bod Australia achieved record total attributable sales of A$3.33m in Q2 FY21, a 52% increase on the previous quarter and a 144% rise on Q2 FY20.
Sales for the period were supported by a number of purchase orders from exclusive global partner Health and Happiness Group for the launch of CBD and hemp products in key markets including the Netherlands, France, Italy and the UK as well as increased prescription volumes of medicinal cannabis product MediCabilis.
Bod expects sales growth to continue during 2021 as the company enters additional markets and achieves growth in medicinal cannabis sales in Australia and the UK.
Bod CEO Jo Patterson said: “The progress achieved over the last quarter is a great result for Bod. The company has considerably broadened its international footprint, with new market entries into the Netherlands, France and Italy, [and] extended its product ranges in the UK.
“Further, we have increased sales of our medicinal cannabis products in Australia and are now benefiting from this growth. Demand for our medicinal cannabis, CBD and hemp products continues to escalate and we expect binding purchase orders to increase during the current period and the remainder of FY21.”
by MARTIN LANEJANUARY 18, 2021
A team of Australian and New Zealand scientists have discovered a way of increasing the absorption of CBD in the blood of mice by almost half and in the brain by a quarter.
CBD is thought to have therapeutic benefits for some brain disorders because it reduces inflammation and acts as an antioxidant, but it is hard for the body to absorb when taken orally.
To address this problem, researchers from Curtin, Newcastle and Otago Universities produced CBD microcapsules, with the compound encapsulated in a gel.
They gave the capsules to mice along with capsules of deoxycholic acid, which increases absorption in the body, and measured levels of CBD in their blood and brains after 20 minutes, one hour, and three hours.
Compared with unencapsulated CBD oil, the new method increased the amount of CBD in the blood by an average of 47%, and in the brain by an average of 25%, according to the team.
With the new capsule combination, the peak concentration of CBD in the brain was 300% higher than with CBD oil, they added.
The peer-reviewed study was financially supported by Zelira Therapeutics.
by MARTIN LANEJANUARY 14, 2021
Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in support of Project Twenty21, Europe’s first and largest national medical cannabis registry.
By the end of 2021, Project Twenty21 aims to recruit up to 20,000 patients suffering from conditions including anxiety, chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, substance use disorder and Tourette’s Syndrome. It will help them access subsidized medical cannabis while simultaneously gathering evidence of efficacy.
Cannatrek will supply medicinal cannabis flowers for the project via LYPHE Group (Astral Health UK) which will be crushed and inhaled via a vaporizer.
Cannatrek CEO Tommy Huppert said: “For us it opens up international trade pathways in what is still a nascent industry. Project Twenty21, with 20,000 patients, represents a very big study and will produce lots of valuable data for Cannatrek and for the industry.”
He added: “Cannatrek is an important part of the supply chain for this study. Supply chains are being created very rapidly worldwide and we want to be front and centre of them.”
Chief commercial officer at LYPHE Group Chris Ashton said: “Project Twenty21 is an incredibly important study in the UK and presents a great opportunity for the industry to demonstrate with valuable data the effectiveness and safety of using medical cannabis.”
by MARTIN LANE JANUARY 13, 2021
Medicinal cannabis and industrial hemp firm ECS Botanics has signed a binding term sheet to acquire medical cannabis cultivator Murray Meds (MM).
Murray Meds has a fully licensed medicinal cannabis cultivation and manufacturing facility in Victoria with permits to cultivate and produce 3,500 grams of medical cannabis and a Cultivation, Research and Manufacturing Licence from the Australian Office of Drug Control.
It also holds a TGA GMP manufacture licence for dried flower, oils and tinctures.
Under the terms of the deal, ECS will own 100% of the issued capital in Murray Meds Pty Ltd and Flowerday Farms Pty Ltd.
ECS managing director Alex Keach said: “MM and ECS share a view on industry methods and a vision for the future. As a combined group we are positioning to become the largest and most geographically diversified cannabis producer in Australia.”
Murray Meds managing director Nan-Maree Schoerie added: “Both organisations are very grounded in their approach to delivering affordable medical cannabis as naturally and sustainably as we can, with shared values and an inherent drive to deliver for patients and shareholders.”
by SIMON PETTINGER JANUARY 12, 2021
Cymra Life Sciences chief operating officer Simon Pettinger argues cannabis companies need to think differently to jump the government’s regulatory hurdles and deliver cost-effective products to patients.
Car racing teams are always searching for incremental improvements to get a few milliseconds advantage, but once every few generations one team makes a dramatic change by thinking about solving a problem through a completely new lens. That’s how we at Cymra Life Sciences are thinking about cannabis.
Crops such as tomatoes, cucumbers and wheat have had hundreds of years of commercial development, while medicinal cannabis has had less than a decade and has been tightly controlled by government restrictions/legislation. It is essentially a new commercial crop.
Cymra’s head of breeding Matt Turner, who has more than 30 years of plant breeding experience, states: “Cannabis has been and continues to be restricted by governments around the world, hampering the speed of innovation around genetic improvement. The opportunity to make cannabis a more efficient and cost-effective crop to reduce costs for patients has huge worldwide potential.”
As one of the few worldwide companies focused on genetics, we set out to breed a plant that would make the agricultural efficiency of medicinal cannabis possible. Once this occurs at scale, patients will have affordable access to potentially beneficial medicines.
Of course, there will always be high-end segments of the cannabis industry who believe in premium indoor flower for smoking. However, we believe it is not sustainable for a patient who may have to pay more than $300 a month for their pain medication in Australia (we acknowledge that government regulation also plays a considerable part in the high patient costs).
Through innovative breeding we believe Australian cannabis cultivators can produce cheaper medicines and continue to operate in a high-cost country such as Australia. We set out to do this by focusing on plant agronomics, breeding new cannabis varieties with better input traits, that deliver agronomic efficiency gains, increased yields and resistance to pests and disease.
The industry has broadly welcomed the Therapeutic Goods Administration’s decision to down schedule low-dose CBD – with some important caveats.
On Wednesday, the TGA announced a significant change in its final decision, with the maximum dose increased to 150mg/day, up from the 60mg/day it signalled in its interim decision in September.
The implementation date of the down scheduling was also brought forward from June 1 to February 1, 2021.
Medicinal Cannabis Industry Australia (MCIA) welcomed the change as providing the industry with the flexibility to develop products for the Schedule 3 registered pathway.
However, it said it would continue to work with the TGA with a view to lifting the dose to 300 mg/day as “this is the threshold at which higher quality evidence accumulates around CBD efficacy, in the absence of significant safety concerns”.
MCIA chair Peter Crock added: “Down-scheduling CBD will benefit patients by allowing them to move from the illicit market and providing easier and more affordable access to high-quality products.”
While noting products will require TGA approval and inclusion on the Australian Register of Therapeutic Goods (ARTG), along with a number of other restrictions, Crock said the decision will provide a pathway for the industry to develop products for this market.
“If fewer consumers seek out illicit CBD products, which have unknown content and quality, then this move ultimately promotes greater safety for patients, which has to be the priority,” he added.
The Australian Medicinal Cannabis Association (AMCA) also welcomed the decision, but noted no medicines currently meet the criteria for a Schedule 3 medicine.
It cited the example of Epidyolex, a CBD-containing product currently registered on the ARTG which contains cannabidiol in a concentration of 100mg/ml, but with a stated starting dose of 2.5mg per kilogram twice daily, which equates to 300-350mg per day for a 60-70 kilogram adult.
AMCA secretary Teresa Nicoletti added: “That being the case, Epidyolex remains a Schedule 4 medicine at its starting dose or higher, and patients will not be able to access it as a Schedule 3 medicine. Based on the requirement for ARTG registration, no CBD medicine is currently available which could be supplied [over the counter].
Ultimately, Schedule 3 CBD medicines will only be available if companies invest in generating the comprehensive data packages of quality, safety and efficacy that would be required to support registration on the ARTG.
“In the meantime, we anticipate patients will continue to access CBD as a Schedule 4 medicine, while the industry waits to see whether companies have any interest in working towards ARTG registration.”
Elixinol Global executive director and group CEO Oliver Horn described the TGA’s decision to increase the maximum daily dose as a “big surprise for the better”, but said it still left Australia lagging behind the rest of the world when it comes to consumer access.
He said: “The good news is that more people will have access to safe and effective CBD products now. However, the TGA’s approach is not reflective of the overall global trend and in particular the regulatory frameworks recently confirmed by the European Commission, which classifies CBD as food.
“Under the EU’s ruling, product suppliers have to demonstrate stringent safety standards but not efficacy. Even under the new TGA ruling, and with an increased dosage, proving efficacy for specific indications will prove challenging and will increase the barriers to entry into the Australian market.
“The vast illegal supply of CBD products from online suppliers into Australia will continue to exist simply because it’s more convenient, easily accessible and likely to be cheaper.
“The TGA ruling misses an opportunity to create a compliant, legal and buoyant domestic CBD market by demanding proof of efficacy and over-regulating the market. It’s a step forward, but global markets are moving forwards faster.”
Bod Australia revealed it has established a medical advisory board to explore the possibilities created by the down scheduling, with Lambert Initiative academic director Iain McGregor and head of neurology at Gold Coast University Hospital, Arman Sabet, among the board members.
Chief executive Jo Patterson told Cannabiz the company would initially pore through academic and medical literature to see if there is material supporting efficacy at 150mg.
She said Bod already has a CBD isolate targeting stress, anxiety and sleep disorder that it will look to register on the ARTG.
“Our ambition is to get a product to market as soon as possible,” Patterson said. “We will sit down with the TGA in the new year and discuss what sort of indication we are looking at for a registration.
“If there is enough literature in the public domain then the task of clinical trials may not be required. But if we do have to go down the clinical path trial, we will. We already have trials designed so if we need to go to phase 2 or phase 3 trials we are ready.”
Bod already has data from observational trials that provided “good insights into dosage and efficacy”, she added.
The listed company said it would also explore opportunities for its consumer-focused CBD and hemp products.
FreshLeaf Analytics regulatory specialist Tony Whittaker warned there were still hurdles for the industry to jump. He said: “The TGA has exacting standards, which will present a significant challenge to this young industry. We look forward to working with TGA to clarify the requirements for over-the-counter CBD products and navigating the path to approval and commercialisation.”
Tim Drury, the director of Southern Cannabis Holdings, which owns FreshLeaf, added: “Low-dose CBD has the potential to become a significant market in Australia for cannabis products.
Companies wanting to compete in this space need to overcome substantial challenges – demonstrating safety, efficacy and quality of manufacturing – but the first to do so will be best positioned to succeed in a market that will, by our estimation, exceed A$200 million per annum.”
by Emma Castle, 14 December
Australian biotechnology company CannaPacific is working in partnership with the CSIRO to trial novel encapsulation technologies for medicinal cannabinoids.
The objective of the trial is to find new encapsulation technology that reduces variability and increases bioavailability.
Dr Alison White, inventor of the technology and CSIRO-AIBN postdoctoral research fellow, said mineral-based thin shells were used to completely surround the cannabinoid with a protective barrier to form a microcapsule.
“This barrier is designed to prevent premature release of the drug, and allows a higher level of control over where and when the drug is released. By controlling the dissolution rate of the microcapsules, we anticipate a more consistent delivery of the cannabinoids into the bloodstream,” said White.
The greater control the technology will provide is anticipated to remedy the current inconsistency of oil-based cannabinoid products. When coupled with optimised formulations of specific cannabinoid medicines, this improved delivery should reduce variability and increase efficacy.
by Martin Lane, 14 December
OnTracka has struck deals for the launch of a white-labelled cannabis tracking app and connecting portal that will see a minimum of 12 prescribing doctors adopting OnTracka technology to power their clinics.
Founder Chad Walkaden (pictured) said the move will give their patients access to the best health care in Australia.
Under the arrangement, prescribing doctors subscribed to OnTracka Enterprise will be the first in the world to benefit from The Portal, the Sydney tech start-up’s second product. Prescribing doctors will encourage their patients to download and populate the app with data including dosage, side effects, exercise, mood and overall health.
The doctor will be able to access the data in real-time via the secure portal and use it to track the patient’s progress and inform their ongoing health care plan during consultations, improve compliance and safety around dosing as well as prescription management.
Patients will be able to invite other health professionals involved in their care to access their data to better inform their treatment recommendations.
by Martin Lane, 10 December
After last week’s decision by the US House of Representatives to end federal marijuana prohibition, on Wednesday it passed a bill to reduce barriers and expand scientific research into medical cannabis.
The move would enable researchers to study medical cannabis products sold in states where it is legal in order to better understand their impact and encourage more doctors to prescribe it.
Unlike the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, the Medical Marijuana Research Act attracted strong bipartisan support, but it is still likely to come unstuck when it reaches the Republican-controlled Senate.
by Steve Jones, 10 December
EXCLUSIVE: Three medicinal cannabis products publicly named by the Therapeutic Goods Administration as having failed to comply with required standards have been exonerated by third party analysis in a development that will increase pressure to produce standardised lab testing across Australia.
The disparity in test results will also concern the TGA which in September stated that five products were found to be stronger or weaker than permitted under Therapeutic Goods Order 93 (TGO93) regulations.
by Martin Lane, 8 December
The Therapeutic Goods Administration approved more than 6,300 medicinal cannabis prescriptions in October, the highest total in 2020, according to the latest data.
Figures published by the TGA revealed 6,356 prescriptions were approved through the Special Access Scheme, beating the previous record of 6,206 in September.
It brings the total number of SAS-B approvals in 2020 to 52,151.
In total, the TGA has now approved more than 80,000 SAS-B applications for unapproved medicinal cannabis products.
The number of Authorised Prescribers rose from 146 to 149 as at November 30.
by Martin Lane, 7 December
Australian Natural Therapeutics Group (ANTG) has been granted a licence in New South Wales to produce large quantities of medicinal cannabis oil for commercial use – a move which it says will ultimately mean more affordable access for Australian patients.
ANTG CEO and founder Matt Cantelo hailed it as a victory for the buy-local movement.
“Allowing more Australian cultivation of oil for the commercial market will be a major turn for the local industry, which traditionally has high barriers to entry,” he said.
ANTG’s growing and manufacturing facility, at an undisclosed location on the outskirts of Armidale, is already producing three strains of cannabis flower as well as oil extract for research and clinical trials.
Speaking after the company was granted GACP and GMP-accreditation, Cantelo said: “The difficulty in acquiring commercial licensing has led to a saturation of the Australian medicinal cannabis market from countries such as Canada, where companies are not required to meet the same level of restrictions placed on Australian businesses.”
by Martin Lane, 4 December
Cannatrek has signed a multi-year supply agreement to export dried cannabis flowers to German-based Nimbus Health.
The Australian medicinal cannabis producer will supply an initial 200 kgs to Nimbus, with the potential to increase to larger commercial quantities as distribution channels are established across Germany and other European regions.
The first batch of Cannatrek’s dried flowers is planned for shipment in the first half of 2021 and will be used in a range of medicines to treat pain, anxiety, sleep disorders and depression.
Cannatrek CEO Tommy Huppert said the move represents a significant step in the company’s growth plans and a sign of the growing popularity of Australian product.
“We are thrilled to be supplying such an important German partner, which gives us a toehold in the large European market. Cannatrek’s brand will arrive in Europe early next year.”
“Australia is a great place to grow medicinal cannabis because of its ample, hot sun that produces excellent terpene profiles and quality products.”
by Rhys Cohen, 3 December
In the second of a two-part investigation into the TGA’s handling of medicinal cannabis advertising complaints, Cannabiz editor-at-large Rhys Cohen analyses the body’s own data to explore how effective its procedures are and suggests industry self-regulation may be the best way forward.
by Martin Lane, 3 December
The United Nations Commission on Narcotic Drugs has accepted a World Health Organisation recommendation overnight to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
In a move which could have far-reaching implications for the global medicinal cannabis industry, the Vienna-based UN agency voted 27-25 in favour, with one abstention.
Under the UN’s system, Schedule IV substances are considered the most dangerous and addictive drugs. Cannabis will now be classified under Schedule I, which is the least restrictive drug classification.
The schedules balance a drug’s medical application against any harm it might cause.
While the vote does not leave the way clear for member nations to legalise cannabis under the international drug control system, taking cannabis off the strictest schedule – and the tacit acknowledgement of its medical benefits – could lead to the loosening of international controls and boost campaigns to legalise medicinal cannabis around the world.
by Emma Castle, 2 December
New research shows cannabidiol (CBD) is safe for driving and the effects of THC fade in just four hours in a huge boost for drug-driving reform campaigners.
The study, led by the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney and conducted at Maastricht University in the Netherlands, was published today in the Journal of the American Medical Association.
Lead author Dr Thomas Arkell said: “These findings indicate for the first time that CBD, when given without THC, does not affect a subject’s ability to drive. That’s great news for those using or considering treatment using CBD-based products.”
The Academic Director of the Lambert Initiative Professor Iain McGregor said the results prove the current laws in Australia are not fit for purpose: “With rapidly changing attitudes towards medical and non-medical use of cannabis, driving under the influence of cannabis is emerging as an important and somewhat controversial public health issue."
by Martin Lane, 24 November
Former Federal Green Party leader Dr Richard Di Natale has been named as the inaugural chair of the newly established Healthcare Practitioner/Patient Advisory Council. The group will provide independent advice to and engage with the Australian medicinal cannabis industry, medical experts, and patient advocates to raise awareness of the applications of medicinal cannabis.
Di Natale said: “This council will ensure there continues to be a strong focus on facilitating patient access to medicinal cannabis. I look forward to engaging with colleagues from the health, research and patient advocacy sectors to increase awareness of medicinal cannabis to Australians and to shape policy to support education and awareness of medicinal cannabis.”
Australian Medicinal Cannabis Association (AMCA) chair Lucy Haslam said: “We are delighted to see the establishment of the Healthcare Practitioner/Patient Advisory Council with Dr Richard Di Natale as the inaugural chair, along with other respected individuals in this field representing patients, their healthcare practitioners, advocates and researchers.
Dr Di Natale has been a strong supporter of patient access to medicinal cannabis for many years since advocating for legislative change for people like Dan Haslam in 2014, and to see him continue his advocacy beyond his parliamentary career demonstrates just how committed he continues to be.
We see this council as another step in making real progress towards improving awareness and facilitating patient access to safe and affordable medicinal cannabis for Australian patients.”
by Steve Jones, 19 November
The industry has been urged to drive out ‘cowboys’ by informing authorities of illegal advertising and exposing baseless medical claims, particularly those made by celebrities.
The Therapeutic Goods Administration said it was striving to tackle the problem, but admitted it was struggling to win the battle.
TGA boss John Skerritt said the health regulator has received 400 complaints relating to the advertising and supply of medicinal cannabis by “websites and clinics”. “This partly reflects that it’s a new industry and partly because there are some cowboys,” he said.
While advertising of medicinal cannabis products by Australian firms is banned, the TGA does not have jurisdiction over offshore firms marketing locally.
Among the major frustrations are endorsements and claims made by celebrities surrounding CBD.
TGA first assistant secretary of regulatory health, Gillian Mitchell, called on the industry to “drown out” celebrity messaging.
Speaking during this week’s PharmOut Medicinal Cannabis Conference, Mitchell said a newly drawn up list of priorities for advertising compliance again included medicinal cannabis.
by Steve Jones, 17 November
The top official overseeing medicinal cannabis in Australia has vowed to continue to ease the administrative burden on industry after conceding the current demands surrounding permit applications are “excessive”.
John Skerritt, who heads the Therapeutic Goods Administration and Office of Drug Control (ODC), said consultation is underway on a simplified process that will demand far less from applicants.
He also confirmed that a consultation period would start before the end of the year over proposals to require imported products to be GMP compliant.
Skerritt told the PharmOut Medicinal Cannabis Conference that feedback from the industry had suggested the permit process was “overly complex”, a sentiment also shared with Professor John McMillan during his review last year of the Narcotic Drugs Act.
Skerritt appeared to acknowledge that the current process – which requires an inordinate amount of time-consuming, complex and repetitive paperwork – needed reform.
“The excessive caution and high level of prescription of what was required was really a function of the fact that it was a new scheme and lawmakers were very cautious and worried about diversion of medicinal cannabis,” he said.
by Emma Castle, 16 November
FreshLeaf Analytics MD Cassandra Hunt:
Speaking at the PharmOut Medicinal Cannabis Conference, she unpacked Freshleaf’s latest market report and encouraged the audience to pursue ‘differentiation by innovation’.
Hunt said: “The majority of companies focus on offer and product performance, but the ones who get the greatest returns knit together five types of innovation.”
She advised delegates to: 1. Gather some inspirational insights around unmet needs from patients and healthcare professionals; 2. Select your innovation platform; 3. Consider types of innovation that tend to get overlooked; 4. Knit together four types of innovation; and 5. Revisit reasonably often, adding innovation is “not a set and forget exercise”. “Innovation doesn’t have to be a heavy drain on resources,” added Hunt.
Quoting research by innovation consultants Doblin, she said innovation could be broken down into ‘configuration’, including innovation around the profit model, network, structure and business processes; ‘offer’ including distinctive aspects of the product performance and product system; and ‘experience’, including service, channel, brand and engagement.
by Martin Lane,16 November
Federal health minister Greg Hunt has said government reforms have helped the Australian medicinal cannabis sector grow to be worth $1.8 billion, but called on the industry to work with him to deliver further growth domestically and overseas.
Opening the Medicinal Cannabis Conference 2020 this morning, Hunt said legalisation in 2016, an emergency national inventory to support patients and faster regulatory pathways had allowed new products, providers and developers into the Australian market..........
Hunt said ".......the Government’s task now is to help the industry register more products and develop the domestic market.
He told delegates: “I’m open to your ideas. What are the next steps that you need to see from the Australian Government? I may not accept all of them, but I want to hear the ideas.”
by Steve Jones, 12 November
The Australian cannabis sector must put clinical research and product innovation at its core as it enters a new phase of growth and maturity, according to senior business leaders.
But it must also tackle familiar issues that continue to hamper progress and frustrate local producers.
In a wide-ranging discussion at the GCI cannabis summit, industry executives identified different quality standards for local and imported products, and the promotion of cannabis as a “cure-all” medicine, as on-going issues that need addressing.
The need for clinical trials and new product was also imperative, with companies needing to demonstrate their potential to attract funds from increasingly savvy investors.
by Steve Jones, 12 November
The medicinal cannabis industry is still suffering from erroneous claims that CBD and THC hold the key to a multitude of conditions for which there is no evidence, a senior executive has warned.
Cann Group chief operating officer Shane Duncan said the “cure-all” message pushed by some had alienated GPs and was still causing health organisations to dismiss the medicine.
Speaking at the GCI cannabis summit, Duncan also reiterated the need for imported product to be held to the same standards as local medicine, a view shared by Little Green Pharma chief executive Fleta Solomon.
If the disparity in quality requirements continues, Australian manufacturers could be the victims of a price war that risks “bastardising” the local industry, she said.
by Emma Castle, 11 November
United In Compassion is calling for pledges of support for its planned Medicinal Cannabis Symposium to be held on the Sunshine Coast in August 2021.
Symposium organiser and United in Compassion founder Lucy Haslam said: “We are asking our industry partners to pledge support so that planning can begin in earnest. We are aware that if Covid 19 prevails and we experience another wave, a face-to-face symposium could be in jeopardy and would need to be postponed again or evolve into a virtual event.
“This means that pledges are important. There is a necessary long lead-up time to prepare an event of this size. If the symposium eventuates, those pledges will need to be fulfilled. If the symposium is cancelled, those pledges will not result in loss for you or your organisation.”
Haslam added that, as United in Compassion is a registered charity, all pledges are fully tax-deductible.
The symposium will include a full-day conference for nurses, three-day trade exhibition, networking welcome event, two-day general symposium, gala dinner event and an exclusive event for medical practitioners and health professionals hosted by the Society of Cannabis Clinicians Australian Chapter.
To pledge support for the symposium, or for more information, please click the button below.
by Saxon Wyatt, 9 November
" even with the ODC and TGA helping to move the industry in the right direction, the every-state-for-itself attitude is making national reform a little hazy. A case in point was the Greens’ efforts to make medicinal cannabis use a defence against drug-driving convictions being voted down in the NSW parliament.
".....we need to shift the perception of cannabis in this country from dangerous to desirable. Undoing all the fake news from the last century and breaking misconceptions that the ‘evil weed’ is a gateway to harder drugs, pedalled by low-life bikie gangs."
by Emma Castle, 4 November
The Australian Medicinal Cannabis Association (AMCA) and The Society of Cannabis Clinicians of the USA have announced the Australian chapter of The Society of Cannabis Clinicians.
At SCCAC’s inaugural meeting on 3rd November Dr James Connell (pictured) was elected president with Dr Joel Wren named vice president of the association.
The formation of the Society of Cannabis Clinicians Australian Chapter (SCCAC) follows the significant growth in prescribers and prescriptions since medical cannabis was legalised in 2016.
by Steve Jones, 5 November 2020
The Therapeutic Goods Administration approved almost 6,000 medicinal cannabis prescriptions in October, a slight decline from September but still up sharply year-on-year, latest data has shown.
Figures published by the TGA revealed 5,972 prescriptions were approved through the Special Access Scheme, down 4% from the previous month’s record of 6,206.
by Tegan Scates HIgh on Hemp Founder), 4 November 2020
In today’s market, Australians have access to a range of options for acquiring medical cannabis, whether legally or illegally. CBD remains one of the most sought-after medical cannabis products, thanks to its lack of hallucinatory effects and much-touted health benefits.
Since the legal route still contains several roadblocks to access, many Australians are turning to black market online sellers for the procurement of CBD products. Other avenues include personal connections, select health and wellbeing stores, and even multi-level marketing schemes.
by Steve Jones, 5 November 2020
Cannabidiol should remain under the guidance of doctors but exempt from the Special Access Scheme, a leading GP has said, as calls grow for a re-think on the down scheduling of low-dose CBD.
An interim decision to allow low doses to be sold without a prescription as a schedule 3 medicine was made in September, with a final ruling by the Therapeutics Goods Administration expected later this month.
Among the key industry concerns is that the current maximum dose set by the TGA – 60mg per day – is simply too low and will restrict the ability to bring products to market.
by Steve Jones, 15 October 2020
by Emma Castle, 7 October 2020
by Emma Castle, 7 October 2020
by Rhys Cohen, 6 October 2020
by Steve Jones, 6 October 2020
by Emma Castle, 29 September 2020
by Martin Lane, 9 September 2020
by Emma Castle, 8 September 2020
by Emma Castle, 7 September 2020
by Helen Kapalos, 2 September 2020
by Rhys Cohen, 1 September 2020
by Cannabiz Team, 1 September 2020
by Martin Lane, 18 August 2020
by Martin Lane, 17 August 2020
by Josie Tutty, 13 August 2020
by Steve Jones, 12 August 2020
by Josie Tutty, 12 August 2020
Speaking to Cannabiz about the launch, Teresa Nicoletti said AMCA represents the broad interests of the industry: “It’s not just about industry players, companies that have a vested interest in setting up medicinal cannabis businesses and have profitability as the goal,” she said. “We look at it more broadly because to have a viable industry, it involves a number of stakeholders including doctors, patients, nurses and caregivers.”
AMCA chair Lucy Haslam: “We’re all very patient centric, our end goal is to get to a place where Australian patients have the best system, where it’s easy to go to a doctor and get a prescription for medicinal cannabis. You can readily afford it. You don’t have to wait ages for it. We want all of that for Australian patients. And I think that’s what’s united us all in AMCA.